Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development
Rapid vaccine development in response to an outbreak of a new emerging infectious disease (EID) is a goal targeted by public health agencies worldwide. This goal becomes more complicated when there are no standardized sets of viral and immunological assays, no accepted and well-characterized samples...
Main Author: | Christine C. Roberts |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-10-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2019.1634992 |
Similar Items
-
Assay Challenges for Emerging Infectious Diseases: The Zika Experience
by: Christine C. Roberts, et al.
Published: (2018-10-01) -
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus
by: Joel N. Maslow
Published: (2017-12-01) -
Zika Vaccine Development—Current Progress and Challenges for the Future
by: Joel N. Maslow
Published: (2019-07-01) -
Recent Advances in Zika Virus Vaccines
by: Himanshu Garg, et al.
Published: (2018-11-01) -
Current trends in Zika vaccine development
by: Francisco A. Lagunas-Rangel, et al.
Published: (2017-07-01)